IPO
Inventera Inc.
인벤테라
Stock page →What the company does
Develops Invinity, a polysaccharide-based nanostructure drug delivery platform, and MRI contrast agents. The filing describes a specialist contrast agent aimed at unmet medical needs.
Themes:Biotech (new drugs)
- Market
- KOSDAQ
- Price range
- ₩12,100 – ₩16,600
- Offer price
- ₩16,600
- Subscription
- Mar 23 – Mar 24
- Payment date
- Mar 26, 2026
- Listing
- Apr 2, 2026
- Shares offered
- 1,180,000
- Raising
- ₩14.3B
- First day
- ▲ +112.3% ₩35,250
- First close vs the offer price
Lead managers: NH Investment & Securities
Other underwriters: 유진증권
Filings
- [기재정정]투자설명서Mar 19, 2026Open on DART ↗
- [발행조건확정]증권신고서(지분증권)Mar 19, 2026Open on DART ↗
- 투자설명서Mar 13, 2026Open on DART ↗
- [기재정정]증권신고서(지분증권)Feb 13, 2026Open on DART ↗
- 증권신고서(지분증권)Jan 30, 2026Open on DART ↗
How a Korean IPO works: institutions bid first (the demand forecast), which sets the final offer price; then individuals subscribe for two days through the lead managers' brokerage accounts; shares start trading on the listing date.
Dates and prices can change until the final terms are filed. Not financial advice. · Updated Oct 16, 2026 · IPO calendar